Emmaus (NASDAQ: EMMA) sets Endari exclusive supply terms with NeoImmuneTech

Rhea-AI Filing Summary

Emmaus Life Sciences has entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT), building on a prior license that grants NIT exclusive rights to market and distribute Endari for sickle cell disease in the U.S., its territories and possessions, and Canada.

The new agreement provides that, once the License Agreement’s “Effective Date” occurs, Emmaus will supply Endari and any generic equivalents exclusively to NIT, and NIT will, with limited exceptions, purchase all of its product requirements from Emmaus at a price equal to Emmaus’ production cost plus a specified double‑digit percentage margin.

The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and may never be reached. Either party may terminate the License Agreement if the Effective Date has not occurred by October 1, 2026, unless the delay results from wrongful acts by Emmaus.

Insights

Biopharma partnership and contracts analyst

Emmaus formalizes Endari supply terms with NIT, contingent on regulatory approvals.

The company has signed an Exclusive Supply Agreement tied to an earlier license that granted NeoImmuneTech exclusivity to market and distribute Endari for sickle cell disease in the U.S. and Canada. Emmaus will be the sole supplier, and NIT will, with certain exceptions, source all product needs from Emmaus.

Pricing is defined as Emmaus’ cost of production plus a specified double‑digit percentage margin, establishing a structured economic framework once the arrangement becomes effective. However, the License Agreement’s Effective Date requires NeoImmuneTech to secure necessary regulatory approvals and meet other stated conditions, so commercial activity under these contracts is not assured.

The License Agreement can be terminated by either party if the Effective Date has not occurred by October 1, 2026, unless the delay is caused by Emmaus’ wrongful acts. Future company filings describing regulatory progress or confirmation of the Effective Date would clarify whether this supply and distribution structure actually becomes operational.

false 0000822370 0000822370 2026-03-02 2026-03-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 2, 2026

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35527		87-0419387
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class		Trading Symbol		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement

Reference is made to the description of the License and Exclusive Distribution Agreement, or License Agreement, dated as of December 24, 2025 between Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” and the “company”) and NeoImmuneTech, Inc. (KOSDAQ: 950220.KQ), or NIT, reported in our Current Report on Form 8-K filed with the Securities and Exchange Commission on December 31, 2025, which description is incorporated herein, pursuant to which we granted NIT an exclusive (including as to Emmaus) license to all our rights to market, sell and distribute Endari® (prescription grade L-glutamine oral powder) and any generic equivalents, or the Products, in sickle cell disease, or the Field, in the U.S. and its territories and possession and Canada, referred to as the Territory. On March 2, 2026, Emmaus and NIT entered into the Exclusive Supply Agreement contemplated by the License Agreement. Subject to the occurrence of the “Effective Date” of the License Agreement, pursuant to the Exclusive Supply Agreement we will agree to supply exclusively to NIT, and NIT will agree, subject to certain exceptions, to purchase exclusively from us all of NIT’s requirements for the Products under the License Agreement at a purchase price based upon our cost of production plus a specified double digit percentage margin.

The Effective Date of the License Agreement is subject to NIT’s obtaining the necessary regulatory approvals and licensing to sell and distribute the Product and other specified conditions, and there is no assurance that the Effective Date will occur. The License Agreement may be terminated by either party if the Effective Date does not occur by October 1, 2026 unless the failure to occur is due to our wrongful acts.

The foregoing descriptions of certain material terms of the License Agreement and of the material terms of the Exclusive Supply Agreement are not complete and are qualified by reference to the full text of the same, copies of which will be filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Report on Form 10-Q for the three months ended March 31, 2026, respectively, and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the accompanying Index to Exhibits, which information is incorporated herein by reference.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 4, 2026	Emmaus Life Sciences, Inc.
	By:	/s/ WILLIS LEE
		Willis Lee
		Chairman and Chief Executive Officer

2

INDEX TO EXHIBITS

Exhibit Number		Description
104		Cover Page Interactive Date File (embedded within Inline XBRL document)

3

FAQ

What agreement did Emmaus Life Sciences (EMMA) enter with NeoImmuneTech?

Emmaus Life Sciences entered into an Exclusive Supply Agreement with NeoImmuneTech. This agreement supports a prior license granting NeoImmuneTech exclusive rights to market, sell, and distribute Endari and generic equivalents for sickle cell disease in the U.S., its territories, possessions, and Canada.

What products are covered under Emmaus Life Sciences’ Exclusive Supply Agreement?

The agreement covers Endari, a prescription‑grade L‑glutamine oral powder, and any generic equivalents. These products are intended for treatment within sickle cell disease and will be supplied by Emmaus exclusively to NeoImmuneTech once the License Agreement’s Effective Date occurs.

How are prices set under Emmaus Life Sciences’ supply deal with NeoImmuneTech?

Under the Exclusive Supply Agreement, Emmaus will supply products to NeoImmuneTech at a purchase price based on Emmaus’ cost of production plus a specified double‑digit percentage margin. This creates a defined markup structure for all licensed product requirements covered by the agreement.

What conditions must be met for the Emmaus–NeoImmuneTech License Agreement to become effective?

The License Agreement’s Effective Date depends on NeoImmuneTech obtaining necessary regulatory approvals and licensing to sell and distribute Endari, along with other specified conditions. The filing notes there is no assurance these conditions will be satisfied or that the Effective Date will occur.

When can the Emmaus and NeoImmuneTech License Agreement be terminated?

Either party may terminate the License Agreement if the Effective Date has not occurred by October 1, 2026. An exception applies when the failure to reach the Effective Date is due to wrongful acts by Emmaus, in which case this termination right does not apply.

Where will the full Emmaus Life Sciences agreements with NeoImmuneTech be available?

Emmaus plans to file the full License and Exclusive Distribution Agreement and the Exclusive Supply Agreement as exhibits. They will appear in the company’s Form 10‑K for the year ended December 31, 2025, and Form 10‑Q for the quarter ended March 31, 2026.

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB